Safety Events in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis Exposed to Tofacitinib (Xeljanz) or Biologics: Real-World Data from the CARRA Registry

被引：0

作者：

Wang, Li ^{[1
]}

Gandhi, Sampada ^{[2
]}

Dennos, Anne ^{[3
]}

Mundayat, Rajiv ^{[1
]}

Diehl, Annette ^{[1
]}

Vranic, Ivana ^{[2
]}

Balevic, Stephen ^{[4
]}

Correll, Colleen ^{[5
]}

Son, Mary Beth ^{[6
]}

Wu, Eveline ^{[7
]}

Phillips, Thomas ^{[3
]}

Younus, Muhammad ^{[1
]}

Aarts, Janske ^{[1
]}

Beukelman, Timothy ^{[8
]}

机构：

[1] Pfizer Inc, New York, NY USA

[2] Pfizer, New York, NY USA

[3] Duke Clin Res Inst, Durham, NC USA

[4] Duke Univ, Durham, NC 27706 USA

[5] Univ Minnesota, Minneapolis, MN 55455 USA

[6] Boston Childrens Hosp, Boston, MA USA

[7] Univ North Carolina, Chapel Hill, NC 27515 USA

[8] FASTER Med, Birmingham, W Midlands, England

[9] Childhood Arthrit & Rheumatol Res Alliance, Washington, DC USA

来源：

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

408

引用

页码：159 / 160

页数：2